GlycoMimetics
Founded Year
2003Stage
IPO | IPOTotal Raised
$63MDate of IPO
1/10/2014Market Cap
0.18BStock Price
3.09Revenue
$0000About GlycoMimetics
GlycoMimetics is developing small molecule drugs that mimic the actions of carbohydrates using glycobiology. The company is focusing its initial efforts on therapeutics to treat inflammatory diseases such as cystic fibrosis and cancer.
Missing: GlycoMimetics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: GlycoMimetics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing GlycoMimetics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
GlycoMimetics is included in 2 Expert Collections, including Cancer.
Cancer
1,179 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
GlycoMimetics Patents
GlycoMimetics has filed 52 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immune system
- Immunology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/28/2018 | 1/10/2023 | Clusters of differentiation, Immune system, Inflammations, Immunology, Cell biology | Grant |
Application Date | 12/28/2018 |
|---|---|
Grant Date | 1/10/2023 |
Title | |
Related Topics | Clusters of differentiation, Immune system, Inflammations, Immunology, Cell biology |
Status | Grant |
Latest GlycoMimetics News
Dec 29, 2022
News provided by Share this article Share this article NEW YORK, Dec. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BXRX, KALA, GLYC, PGY, and RNAZ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.) InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment. InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options. SOURCE InvestorsObserver
GlycoMimetics Frequently Asked Questions (FAQ)
When was GlycoMimetics founded?
GlycoMimetics was founded in 2003.
Where is GlycoMimetics's headquarters?
GlycoMimetics's headquarters is located at 101 Orchard Ridge Drive, Gaithersburg.
What is GlycoMimetics's latest funding round?
GlycoMimetics's latest funding round is IPO.
How much did GlycoMimetics raise?
GlycoMimetics raised a total of $63M.
Who are the investors of GlycoMimetics?
Investors of GlycoMimetics include Alliance Technology Ventures, Anthem Capital, New Enterprise Associates, Novartis Venture Funds, Sanofi-Genzyme BioVentures and 5 more.
Who are GlycoMimetics's competitors?
Competitors of GlycoMimetics include Aquinox Pharmaceuticals, Novira Therapeutics, iPierian, Mimetogen Pharmaceuticals, Calyx Therapeutics and 13 more.
Compare GlycoMimetics to Competitors
Novation is focusing on the development of small molecular weight drugs that affect the stability of messenger RNA. Initial development efforts are on the treatment and prevention of cancer and chronic inflammatory diseases.
Oxagen is a biopharmaceutical company that develops small molecule drugs for inflammatory and respiratory diseases.
Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.
Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.
Orexo is a pharmaceutical company, focusing on development of new, patented drugs by combining well-documented substances with innovative technologies, and the development of new treatments for respiratory and inflammatory diseases.
Mimetogen is actively pursuing the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. The company designs and develops small molecule drugs that mimic the effects of neurotrophins, proteins that help maintain the health and growth of many cells and tissues found in the eye. Making drugs that can mimic the large natural molecules may lead to the development of novel approaches to treat degenerative ocular diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration and dry eye.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.